Validation of a symptom scale for COVID-19 patients in ambulatory care
Main Article Content
Keywords
Surveys and Questionnaires, Validation Study, Ambulatory Care, COVID-19
Abstract
Background: A symptom scale can be useful for the standardization of clinical evaluations and follow-up of COVID-19 patients in ambultaroy care. Scale development should be accompanied by an assessment of its reliablility and validity.
Objective: To develop and measure the psychometric characteristics of a COVID-19 symptom scale to be answered by either healthcare personnel or adult patients in ambulatory care.
Material and methods: The scale was developed by an expert panel using the Delphi method. We evaluated inter-rater reliability, where we defined a good correlation if Spearman’s Rho was ≥ 0.8; test-retest, where we defined a good correlation if Spearman’s Rho was ≥ 0.7; factor analysis using principal component methodology; and discriminant validity using Mann-Whitney’s U test. A p < 0.05 was considered statistically significant.
Results: We obtained an 8 symptom scale, each symptom is scored from 0-4, with a total minimum score of 0 and a maximum of 32 points. Inter-rater reliability was 0.995 (n = 31), test-retest showed correlation of 0.88 (n = 22), factor analysis detected 4 factors (n = 40) and discriminant capacity of healthy versus sick adults was significant (p < 0.0001, n = 60).
Conclusions: We obtained a reliable and valid Spanish (from Mexico) symptom scale for COVID-19 ambulatory care, answerable by patients and health care staff.
References
Ritchie H, Mathieu E, Rodés-Guirao L, Appel C, Giattino C, Ortiz-Ospina E, et al. Our World in Data: statistics and Research Coronavirus (COVID-19) Cases. Global Change Data Lab; 2020. Disponible en: https://ourworldindata.org/ covid-cases?country=~OWID_WRL.
World Health Organization. Home care for patients with suspected or confirmed COVID-19 and management of their contacts. World Health Organization Guidelines. 2020. Disponible en: https://www.who.int/emergencies/diseases/ novel-coronavirus-2019/technical-guidance-publications.
Xu H, Huang S, Liu S, Deng J, Jiao B, Ai L, et al. Evaluation of the Clinical Characteristics of Suspected or Confirmed Cases of COVID-19 During Home Care with Isolation: A New Retrospective Analysis Based on O2O. medRxiv. 2020. Preprint. doi: 10.1101/2020.02.26.20028084.
Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708-20. doi: 10.1056/NEJMoa2002032.
Zhang J, Dong X, Cao Y, Yuan Y, Yang Y, Yan Y, et al. Clinical characteristics of 140 patients infected by SARS-CoV-2 in Wuhan, China. Allergy. 2020;75:1730-41.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506.
De Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14(8):523-34. doi: 10.1038/ nrmicro.2016.81.
Rider AC, Frazee BW. Community-Acquired Pneumonia. Emerg Med Clin North Am. 2018;36(4):665-83. doi: 10.1016/j.emc.2018.07.001.
Charles PG, Wolfe R, Whitby M, Fine MJ, Fuller AJ, Stirling R et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community acquired pneumonia. Clin Infect Dis. 2008;47(3):375-84. doi: 10.1086/589754. PMID: 18558884.
Shi SJ, Li H, Liu M, Liu YM, Zhou F, Liu B, et al. Mortality prediction to hospitalized patients with influenza pneumonia: PO(2) /FiO(2) combined lymphocyte count is the answer. Clin Respir J. 2017;11:352-60.
Guo L, Wei D, Zhang X, Wu Y, Li Q, Zhou M et al. Clinical features predicting mortality risk in patients with viral pneumonia: the MuLBSTA score. Front Microbiol 2019;10:2752.
Duca A, Piva S, Focà E, Latronico N, Rizzi M. Calculated Decisions: Brescia-COVID Respiratory Severity Scale (BCRSS)/ Algorithm. Emerg Med Pract. 2020;22(5 Suppl):CD1-CD2.
Haimovich AD, Ravindra NG, Stoytchev S, Young HP, Wilson FP, van Dijk D. Development and validation of the quick covid-19 severity index: a prognostic tool for early clinical decompensation. Ann Emerg Med. 2020;76(4):442-53. doi: 10.1016/j.annemergmed.2020.07.022.
Rodriguez-Nava G, Yanez-Bello MA, Trelles-Garcia DP, Chung CW, Friedman HJ, Hines DW. Performance of the quick COVID-19 severity index and the Brescia-COVID respiratory severity scale in hospitalized patients with COVID-19 in a community hospital setting. Int J Infect Dis. 2021;102:571-576. doi: 10.1016/j.ijid.2020.11.003.
Mudatsir M, Fajar JK, Wulandari L, Soegiarto G, Ilmawan M, Purnamasari Y et al. Predictors of COVID-19 severity: a systematic review and meta-analysis. F1000Res. 2020 Sep 9;9:1107. doi: 10.12688/f1000research.26186.2.
Candal-Pedreira C, Fernández-Villar A, López-Campos JL, Ruano-Ravina A. Escalas pronósticas de morbimortalidad por COVID-19: necesarias pero también fiables. Arch Bronconeumol. 2021;57:62-3. doi:10.1016/j.arbres.2021.02.009.
Project Management Institute. Project management body of knowledge (PMBOK© Guide). 5th ed. Pensylvania: Project Management Institute Inc; 2013. pp. 115, 324.
Argimon JM, Jiménez J. Medición de variables. En: Métodos de investigación clínica y epidemiológica. Argimon J, Jiménez J (eds.); Tercera edición. Madrid; 2004, pp.168-75.
Carvajal A, Centeno C, Watson R, Martínez M, Sanz Rubiales Á. ¿Cómo validar un instrumento de medida de la salud? Anales Sis San Navarra. 2011; 34(1): 63-72. Disponible en: http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1137- 66272011000100007&lng=es.
Rencher AC. Methods of Multivariate Analysis. 2nd edition. New York: Wiley-Interscience; 2002. pp. 408-50.
Arnanz I, Martínez M, Recio S , Blasco R, Benedito T, Sanz M. Las escalas en la COVID-19 persistente. Med Gen Fam. 2021; 10(2):79-84.
Drew DA, Nguyen LH, Steves CJ, Menni C, Freydin M, Varsavsky T et al. Rapid implementation of mobile technology for real-time epidemiology of COVID-19. Science. 2020;368 (6497):1362-7. doi: 10.1126/science.abc0473.
Koh J, Shah SU, Chua PEY, Gui H, Pang J. Epidemiological and Clinical Characteristics of Cases During the Early Phase of COVID-19 Pandemic: A Systematic Review and Meta-Analysis. Front Med. 2020;7:295. doi: 10.3389/fmed.2020.00295.
Lechien JR, Chiesa-Estomba CM, Place S, Van Laethem Y, Cabaraux P, Mat Q et al. COVID-19 Task Force of YO-IFOS. Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019. J Intern Med. 2020;288(3):335-44. doi: 10.1111/joim.13089.
Lapostolle F, Schneider E, Vianu I, Dollet G, Roche B, Berdah J et al. Clinical features of 1487 COVID-19 patients with outpatient management in the Greater Paris: the COVID-call study. Intern Emerg Med. 2020;15:813-7. doi: 10.1007/s11739-020-02379-z.
Menni C, Valdes AM, Freidin MB, Sudre CH, Nguyen LH, Drew DA et al. Real-time tracking of self-reported symptoms to predict potential COVID-19. Nat Med. 2020; 26:1037-40. doi:10.1038/ s41591-020-0916-2.
Ehnhage A, Kölbeck KG, Mossberg B, Juto JE. Nasal and bronchial histamine responsiveness in pollen-exposed patients with seasonal rhinitis. ORL J Otorhinolaryngol Relat Spec. 2002;64(3):191-9. doi: 10.1159/000058024.
Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, Villamizar-Peña R, Holguin-Rivera Y, Escalera-Antezana JP et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis. 2020;34:101623. doi: 10.1016/j.tmaid.2020.101623.
Assessing COVID-19-related symptoms in outpatient adult and adolescent subjects in clinical trials of drugs and biological products for COVID-19 prevention or treatment. United States Department of Health and Human Services issuing body, United States Food and Drug Administration issuing body, Center for Drug Evaluation and Research (U.S.) issuing body, Center for Biologics Evaluation and Research (U.S.) issuing body. USA; Septemb2020; Disponible en: http://resource.nlm.nih.gov/9918232103906676.
Article Sidebar
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors retain their copyright and grant the Revista Médica del IMSS the right of first publication. Articles are distributed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows sharing as long as the author and the original source are properly credited.